Objective To study the changes in the serum levels of Chemerin and Omentin-1 in children with Kawasaki disease (KD) in the acute stage after intravenous immunoglobulin (IVIG) treatment and related clinical significance. Methods A total of 60 children who were diagnosed with KD from January 2015 to April 2019 were enrolled as subjects. Forty healthy children and 40 children with acute infectious diseases were enrolled as the healthy control group and the infection control group respectively. According to the sensitivity to IVIG treatment, the children with KD were divided into an IVIG sensitive group with 51 children and a non-IVIG sensitive group with 9 children. According to the presence or absence of coronary artery lesion, the children with KD were divided into a CAL group with 13 children and a non-CAL group with 47 children. ELISA was used to measure the serum levels of Omentin-1 and Chemerin before and after the treatment. Results The children with KD had significantly higher serum levels of Chemerin and Omentin-1 than the healthy control and infection control groups before treatment (P < 0.05). After 48 hours of treatment, the IVIG sensitive group had a significant reduction in the serum level of Chemerin (P < 0.05), while there was no significant change in the serum level of Omentin-1 after treatment (P > 0.05). Before treatment, the non-IVIG sensitive group had a significantly higher serum level of Chemerin than the IVIG sensitive group (P < 0.05), and the CAL group had a significantly higher serum level of Chemerin than the non-CAL group, while there was no significant difference in the serum level of Omentin-1 between the IVIG sensitive and non-IVIG sensitive groups, as well as between the CAL and non-CAL groups (P > 0.05). Conclusions High serum levels of Chemerin and Omentin-1 may play an important role in the development and progression of KD. Chemerin may be involved in the development of CAL in children with KD. The serum level of Chemerin may be used as a new index for predicting the sensitivity to IVIG treatment.
Key words
Kawasaki disease /
Coronary artery lesion /
Adipokine /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Fioravanti A, Simonini G, Cantarini L, et al. Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease[J]. Rheumatol Int, 2012, 32(5):1481-1482.
[2] 张福庄, 陶红, 王永梅, 等. 心外膜脂肪体积与冠状动脉粥样硬化及左心室舒张功能的相关性研究[J]. 心肺血管病杂志, 2012, 31(1):58-63.
[3] Aksu F, Caliskan M, Keles N, et al. Chemerin as a marker of subclinical cardiac involvement in psoriatic patients[J]. Cardiol J, 2017, 24(3):276-283.
[4] Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J]. Pediatr Int, 2005, 47(2):232-234.
[5] 江载芳, 申昆玲, 沈颖. 诸福棠实用儿科学[M]. 第8版. 北京:人民卫生出版社, 2015:778-788.
[6] Onur I, Oz F, Yildiz S, et al. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women[J]. Angiology, 2014, 65(10):896-900.
[7] Kadoglou NP, Tahmatzidis DK, Giannakoulas C, et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction:KOZANI STUDY[J]. J Cardiovasc Med (Hagerstown), 2015, 16(5):341-346.
[8] Biscetti F, Nardella E, Bonadia N, et al. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease[J]. Cardiovasc Diabetol, 2019, 18(1):74.
[9] Aliasghari F, Izadi A, Jabbari M, et al. Are vaspin and omentin-1 related to insulin resistance, blood pressure and inflammation in NAFLD patients?[J]. J Med Biochem, 2018, 37(4):470-475.
[10] Carrión M, Frommer KW, Pérez-García S, et al. The adipokine network in rheumatic joint diseases[J]. Int J Mol Sci, 2019, 20(17). pii:E4091.
[11] Wolk K, Sabat R. Adipokines in psoriasis:an important link between skin inflammation and metabolic alterations[J]. Rev Endocr Metab Disord, 2016, 17(3):305-317.
[12] Parthasarathy P, Agarwal A, Chawla K, et al. Upcoming biomarkers for the diagnosis of Kawasaki disease:a review[J]. Clin Biochem, 2015, 48(16-17):1188-1194.
PDF(1258 KB)
